Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer

Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3–7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved small molecule inhibitors targeting ALK fusion proteins, drug resistance to ALK kinase inhibitors is a common problem in clinic. Thus, there is an unmet need to deepen the current understanding of genomic characteristics of ALK rearrangements and to develop novel therapeutic strategies that can overcome ALK inhibitor resistance. In this review, we present the genomic landscape of ALK fusions in the context of co-occurring mutations with other cancer-related genes, pointing to the central role of genetic epistasis (gene-gene interactions) in ALK-driven advanced-stage lung cancer. We discuss the possibility of targeting druggable domains within ALK fusion partners in addition to available strategies inhibiting the ALK kinase domain directly. Finally, we examine the potential of targeting ALK fusion-specific neoantigens in combination with other treatments, a strategy that could open a new avenue for the improved treatment of ALK positive lung cancer patients.

[1]  Y. Huang,et al.  Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients , 2016, Oncoimmunology.

[2]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[3]  D. DeLuca,et al.  Mutated Bcr-abl Generates Immunogenic T Cell Epitopes in Cml Patients Nih Public Access Author Manuscript , 2022 .

[4]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[5]  T. Nakajima,et al.  KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only , 2012, PloS one.

[6]  C. Powers,et al.  Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types* , 2002, The Journal of Biological Chemistry.

[7]  R. Bernards,et al.  Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing , 2013, The Journal of pathology.

[8]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[9]  D. Wen,et al.  Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin* , 2001, The Journal of Biological Chemistry.

[10]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[11]  R. Orentas,et al.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  P. Jänne,et al.  Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors , 2015, Cancer Immunology Research.

[13]  William Pao,et al.  Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer , 2014, Nature Medicine.

[14]  A. Wellstein,et al.  Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor , 2009, Oncogene.

[15]  Kentaro Inamura,et al.  Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification , 2017, Front. Oncol..

[16]  V. Tin,et al.  A novel KIF5B‐ALK variant in nonsmall cell lung cancer , 2011, Cancer.

[17]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[18]  R. Salgia,et al.  Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer , 2016, Cureus.

[19]  Y. Yatabe,et al.  Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Asthana,et al.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer , 2015, Nature Medicine.

[21]  Clement M. Lee.  Transport of c-MYC by Kinesin-1 for proteasomal degradation in the cytoplasm. , 2014, Biochimica et biophysica acta.

[22]  I. Lax,et al.  Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions , 2015, Proceedings of the National Academy of Sciences.

[23]  K. Park,et al.  Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  O. Ohara,et al.  Identification of Individual Cancer‐Specific Somatic Mutations for Neoantigen‐Based Immunotherapy of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[26]  F. Lemonnier,et al.  ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. , 2002, Blood.

[27]  K. Inamura.  Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer , 2017, Cancers.

[28]  Yan-Ze Jin,et al.  MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status , 2016, Oncotarget.

[29]  A. Shaw,et al.  Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.

[30]  B. Falini,et al.  Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. , 2000, Blood.

[31]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[32]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Palmer,et al.  FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase , 2015, eLife.

[34]  T. Arakawa,et al.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.

[35]  A. Chella,et al.  microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers , 2015, Proceedings of the National Academy of Sciences.

[36]  G. Inghirami,et al.  The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination , 2008, Nature Medicine.

[37]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[38]  R. Palmer,et al.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.

[39]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[40]  Md Abu Shufean,et al.  ALK: a tyrosine kinase target for cancer therapy , 2017, Cold Spring Harbor molecular case studies.

[41]  S. Chanock,et al.  Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. , 2016, Cancer research.

[42]  Tao Fan,et al.  Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review. , 2016, Molecular and clinical oncology.

[43]  A. Watkins,et al.  Protein–Protein Interactions Mediated by Helical Tertiary Structure Motifs , 2015, Journal of the American Chemical Society.

[44]  Andrew S. Dixon,et al.  Disruption of Bcr-Abl Coiled Coil Oligomerization by Design* , 2011, The Journal of Biological Chemistry.

[45]  Richard Z. Liu,et al.  Coupling an EML4-ALK–centric interactome with RNA interference identifies sensitizers to ALK inhibitors , 2016, Science Signaling.

[46]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[47]  A. Shaw,et al.  Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine , 2015, Clinical Cancer Research.

[48]  W. Jochum,et al.  Clinical Outcome of ALK‐Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co‐Mutations Receiving Tyrosine Kinase Inhibitors (TKIs) , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  Yusuke Nakamura,et al.  Effects of SMYD2‐mediated EML4‐ALK methylation on the signaling pathway and growth in non‐small‐cell lung cancer cells , 2017, Cancer science.

[50]  Joungho Han,et al.  HIP1–ALK, a Novel Fusion Protein Identified in Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[52]  I D Kuntz,et al.  Inhibitors of kinesin activity from structure-based computer screening. , 2000, Biochemistry.

[53]  R. Palmer,et al.  Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.

[54]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[55]  A. Shaw,et al.  Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Roman K. Thomas,et al.  Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants , 2012, Clinical Cancer Research.

[57]  P. Burkhard,et al.  Coiled coils: a highly versatile protein folding motif. , 2001, Trends in cell biology.

[58]  Petr Znamenskiy,et al.  Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications , 2008, Neuropsychopharmacology.

[59]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[60]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[61]  Serafino Pantano,et al.  Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. , 2016 .

[62]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[63]  P. Kim,et al.  Discovery of ALK‐PTPN3 gene fusion from human non‐small cell lung carcinoma cell line using next generation RNA sequencing , 2012, Genes, chromosomes & cancer.

[64]  Ryohei Katayama,et al.  Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. , 2017, Pharmacology & therapeutics.

[65]  E. Hispard,et al.  Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. , 1995, Alcoholism, clinical and experimental research.

[66]  T. Kapoor,et al.  Dynein/dynactin regulate metaphase spindle length by targeting depolymerizing activities to spindle poles , 2004, The Journal of cell biology.

[67]  T. Schroer,et al.  Mycalolide B dissociates dynactin and abolishes retrograde axonal transport of dense-core vesicles , 2015, Molecular biology of the cell.

[68]  H. Peckham,et al.  A Novel Fusion of TPR and ALK in Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[69]  D. Fennell,et al.  Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain , 2014, Proceedings of the National Academy of Sciences.

[70]  Andrew B. Mahon,et al.  An Effective Strategy for Stabilizing Minimal Coiled Coil Mimetics , 2015, Journal of the American Chemical Society.

[71]  S. Albelda,et al.  CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.

[72]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[73]  A. Sokolenko,et al.  Novel ALK fusion partners in lung cancer. , 2015, Cancer letters.

[74]  Hyun-Tae Shin,et al.  Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer , 2017, The Journal of pathology.

[75]  H. Asamura,et al.  Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. , 2017, European journal of cancer.

[76]  E. Campo,et al.  Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells , 2004, Oncogene.

[77]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[78]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[79]  J. Wolchok,et al.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps , 2011, Nature Reviews Cancer.